Search

Latar belakang: Asal tumor suatu efusi pleura maligna perlu diketahui untuk tatalaksana tepat. Etiologi tersering yaitu keganasan paru, payudara, limfoma, dan penyebab lainnya. Penanda spesifik payudara untuk memastikan kasus metastasis payudara di Indonesia yaitu mammaglobin (MGB) dan gross cystic disease fluid protein 15 (GCDFP15). Belakangan ini GATA binding protein 3 (GATA3) dilaporkan memiliki akurasi yang lebih baik. Tujuan: Mengetahui akurasi GATA3 dibandingkan MGB dan GCDFP15 untuk membedakan asal tumor payudara dan non-payudara pada sediaan sitologi blok sel cairan efusi.Metode: Literatur dicari pada basis data Pubmed, Cochrane, Proquest, Scopus, dan EBSCOHost. Didapatkan 7 jurnal yang relevan, lalu ditelaah kritis. Hasil: Dengan berbagai batas nilai positif pada berbagai penelitian tersebut, akurasi GATA3 untuk sediaan sitologi blok sel cairan efusi didapatkan lebih baik secara signifikan dibandingkan MGB dan GCDFP15 dengan sensitivitas 90-93,5% dan spesifisitas 88,5-96,9%. Intensitas pewarnaan GATA3 didapatkan lebih tinggi, dengan kontaminasi pewarnaan latar belakang yang lebih sedikit sehingga pembacaan dapat dilakukan dengan lebih baik. Kesimpulan: Akurasi imunositokimia GATA3 sebagai penanda spesifik payudara untuk menentukan asal tumor pada spesimen sitologi cairan efusi kasus metastasis kanker didapatkan lebih baik dibandingkan MGB dan GCDFP15. Oleh karena itu, GATA3 dapat dipertimbangkan sebagai pengganti MGB dan GCDFP15 untuk penanda spesifik payudara.

We aim to describe the sTIL profiles of Indonesian breast cancer patient and its role in predicting neoadjuvant chemotherapy response.This retrospective cohort study used secondary data from the archive of Anatomic Pathology Department FMUI/CMH. We did total sampling of 62 cases of locally advanced breast cancer cases that were biopsied, had neoadjuvant chemotherapy, and operated on from 2015 to 2020. We collected the clinicopathological data of each sample, measured the sTIL intensity in the biopsy specimen and evaluated the chemotherapy response from the mastectomy specimen using residual cancer burden (RCB) scoring method. Multivariate linear regression determined the independent predictors of RCB score.There were 62 female patients, 45.2% were Luminal-HER2-, 43.5% were HER2+, and 11.3% were triple negative (TN). Most sTIL intensity (59.7%) were low (median 10%; 1%-60%). Moderate-high sTIL intensity was associated with HER2+ type, while low sTIL was with luminal-HER2- (p=0.038). Only 8.1% patients achieved pCR. Statistically different median sTIL intensity in minimal, moderate, and extensive burden group were 28%, 20%, and 8%, respectively (p=0.002). sTIL was an independent predictor for better response (lower RCB score), which were 0.07 (95% CI 0.04-0.09) lower for every 1% increase in sTIL intensity.sTIL intensity was mostly low in Indonesian breast cancer patient. However, it can predict neoadjuvant chemotherapy response, with 0.07 lower RCB score for every 1% increase of sTIL intensity.

Felix Chikita Fredy, Devi Felicia, Alexandra Gabriella*, Gracia Lilihata, Vincent Kane, Sarah Febiana Rahayu, Nurnajmia Curie Proklamartina, Joshua Patrick Mulyadi, Ratna Andriyati, Bhayu Hanggadhi Nugroho, Dexanda Pravian Internship Doctor, Sangatta General Hospital, Sangatta, Internship Doctor, Robert Wolter Mongisidi General Hospital, Manado, Internship Doctor, Tanjung General Hospital, Tanjung, Internship Doctor, Leuwiliang General Hospital, Bogor, Internship Doctor, Mukomuko General Hospital, Mukomuko, Internship Doctor, Kanujoso Dhatiwibowo General Hospital, Balikpapan, Internship Doctor, Singaraja General Hospital, Singaraja, Internship Doctor, Kupang General Hospital, Kupang, Indonesia